Identifying Predictors of Anti-VEGF Treatment Response in Patients with Neovascular Age-Related Macular Degeneration through Discriminant and Principal Component Analysis

被引:5
|
作者
Holz, Frank G. [1 ]
Tadayoni, Ramin [3 ]
Beatty, Stephen [4 ]
Berger, Alan R. [5 ,6 ]
Cereda, Matteo G. [7 ]
Hykin, Philip [8 ]
Hoyng, Carel B. [10 ]
Wittrup-Jensen, Kim [2 ]
Altemark, Andreas [2 ]
Nilsson, Jonas [11 ]
Kim, Kun [12 ]
Sivaprasad, Sobha [8 ,9 ]
机构
[1] Univ Bonn, Dept Ophthalmol, Bonn, Germany
[2] Bayer Pharmaceut, Berlin, Germany
[3] Univ Paris 07, Hop Lariboisiere, AP HP, Dept Ophthalmol,Sorbonne Paris Cite, Paris, France
[4] Inst Eye Surg, Dept Ophthalmol, Waterford, Ireland
[5] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada
[6] St Michaels Hosp, Toronto, ON, Canada
[7] Univ Milan, Luigi Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, Milan, Italy
[8] Moorfields Eye Hosp, NIHR Biomed Ctr Res Ophthalmol, London, England
[9] Kings Coll Hosp London, Dept Ophthalmol, London, England
[10] Radboud Univ Nijmegen Med Ctr, Dept Ophthalmol, Nijmegen, Netherlands
[11] Real World Strategy & Analyt, Mapi Grp, Stockholm, Sweden
[12] AstraZeneca Nord Balt, Hlth Econ, Sodertalje, Sweden
关键词
AURA; Intravitreal ranibizumab; Neovascular age-related macular degeneration; INTRAVITREAL RANIBIZUMAB; VISUAL-ACUITY; OUTCOMES; LIFE; AMD;
D O I
10.1159/000449001
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Objective: AURA was an observational study that monitored visual acuity outcomes following ranibizumab use in neovascular age-related macular degeneration patients over 2 years. The aim of this analysis was to identify factors that were predictive of visual acuity outcomes in AURA. Methods: The correlation between the baseline characteristics, the use of resources and the visual acuity outcomes in AURA was explored using principal component analysis (PCA) and partial least-squares-discriminant analysis (PLS-DA). The response variables analysed were mean change in visual acuity over 2 years (analysed via PCA) and no decline in visual acuity at 2 years compared with baseline (analysed via PLS-DA). Results: The AURA dataset comprised 2,227 patients and 132 variables. Using PCA and PLS-DA, we found that the number of ranibizumab injections, clinic and monitoring visits, number of optical coherence tomography scans and ophthalmoscopies correlated with a change in visual acuity at Years 1 and 2, and are therefore key drivers of treatment success. Conclusion: This is a novel approach to graphically explore relationships between multiple correlated covariates and outcomes in real-life ophthalmology studies. It identified a number of variables that are positively linked with treatment outcomes. (C) 2016 S. Karger AG, Basel
引用
收藏
页码:49 / 55
页数:7
相关论文
共 50 条
  • [41] Anti-VEGF Monotherapy Versus Photodynamic Therapy and Anti-VEGF Combination Treatment for Neovascular Age-Related Macular Degeneration: A Meta-Analysis
    Gao, Yang
    Yu, Tao
    Zhang, Yue
    Dang, Guangfu
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (10) : 4307 - 4317
  • [42] Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review
    Yang, Shiqi
    Zhao, Jingke
    Sun, Xiaodong
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 1857 - 1867
  • [43] Anti-VEGF and Other Novel Therapies for Neovascular Age-Related Macular Degeneration: An Update
    Parravano, Mariacristina
    Costanzo, Eliana
    Scondotto, Giulia
    Trifiro, Gianluca
    Virgili, Gianni
    BIODRUGS, 2021, 35 (06) : 673 - 692
  • [44] Anti-VEGF and Other Novel Therapies for Neovascular Age-Related Macular Degeneration: An Update
    Mariacristina Parravano
    Eliana Costanzo
    Giulia Scondotto
    Gianluca Trifirò
    Gianni Virgili
    BioDrugs, 2021, 35 : 673 - 692
  • [45] Anti-VEGF Therapy Patterns of Neovascular Age-related Macular Degeneration in Shanghai, China
    Shen, Mengxi
    Zhou, Tianyuan
    Fu, Chunyu
    Gu, Xiang
    Xiao, Meichun
    Wang, Fenghua
    Sun, Xiaodong
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [46] Recent advances and future directions for the pharmacogenetic basis of anti-VEGF treatment response in neovascular age-related macular degeneration
    Moeen Riaz
    Paul N. Baird
    Neural Regeneration Research, 2017, 12 (04) : 584 - 585
  • [47] Effects of the COVID-19 pandemic on neovascular age-related macular degeneration and response to delayed Anti-VEGF treatment
    Yeter, D. Y.
    Dursun, D.
    Bozali, E.
    Ozec, A., V
    Erdogan, H.
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 2021, 44 (03): : 299 - 306
  • [48] Recent advances and future directions for the pharmacogenetic basis of anti-VEGF treatment response in neovascular age-related macular degeneration
    Riaz, Moeen
    Baird, Paul N.
    NEURAL REGENERATION RESEARCH, 2017, 12 (04) : 584 - 585
  • [49] Correlation of Baseline Visual Acuity with Outcomes of Treatment with Anti-VEGF in Neovascular Age-Related Macular Degeneration
    Veluswamy, Balaji
    Lee, Andy
    Mirza, Rukhsana G.
    Gill, Manjot K.
    CLINICAL OPHTHALMOLOGY, 2020, 14 : 1565 - 1572
  • [50] Treat and Extend Anti-VEGF Treatment Regimens for Neovascular Age-Related Macular Degeneration: To Stop or Not to Stop?
    Patel, Praveen J.
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2025, 53 (01): : 8 - 10